Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Dynavax Technologies Corporation before investing.

In this article, we go over a few key elements for understanding Dynavax Technologies Corporation’s stock price such as:

• Dynavax Technologies Corporation’s current stock price and volume
• Why Dynavax Technologies Corporation’s stock price changed recently
• Upgrades and downgrades for DVAX from analysts
• DVAX’s stock price momentum as measured by its relative strength

About Dynavax Technologies Corporation (DVAX)

Before we jump into Dynavax Technologies Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Want to learn more about Dynavax Technologies Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Dynavax Technologies Corporation.

Dynavax Technologies Corporation’s Stock Price as of Market Close

As of May 07, 2025, 12:46 PM, CST, Dynavax Technologies Corporation’s stock price was $9.645.

Dynavax Technologies Corporation is down 11.68% from its previous closing price of $10.920.

During the last market session, Dynavax Technologies Corporation’s stock traded between $9.620 and $10.790. Currently, there are approximately 127.95 million shares outstanding for Dynavax Technologies Corporation.

Dynavax Technologies Corporation’s price-earnings (P/E) ratio is currently at 54.6, which is high compared to the Biotechnology industry median of 20.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Dynavax Technologies Corporation Stock Price History

Dynavax Technologies Corporation’s (DVAX) price is currently down 17.91% so far this month.

During the month of May, Dynavax Technologies Corporation’s stock price has reached a high of $11.720 and a low of $9.620.

Over the last year, Dynavax Technologies Corporation has hit prices as high as $14.630 and as low as $9.740. Year to date, Dynavax Technologies Corporation’s stock is down 24.47%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Dynavax Technologies Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 06, 2025,, no analysts have changed their rating of Dynavax Technologies Corporation’s stock over the last month.

Additionally, you'll want to evaluate Dynavax Technologies Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Dynavax Technologies Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Dynavax Technologies Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Dynavax Technologies Corporation (DVAX) by visiting AAII Stock Evaluator.

Relative Price Strength of Dynavax Technologies Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 06, 2025, Dynavax Technologies Corporation has a weighted four-quarter relative price strength of -4.84%, which translates to a Momentum Score of 40 and is considered to be Weak.

Want to learn more about how Dynavax Technologies Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Dynavax Technologies Corporation Stock Price: Bottom Line

As of May 7, 2025, Dynavax Technologies Corporation’s stock price is $9.645, which is down 11.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Dynavax Technologies Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.